A complete explanation of which diseases vorasidenib-VORANIGO is used to treat and its clinical indications

Vorasidenib (trade name VORANIGO) is an oral small molecule targeted drug that is a selective IDH1/2 inhibitor and is mainly used to treat tumors with IDH1 or IDH2 gene mutations. By inhibiting mutant isocitrate dehydrogenase (IDH), vorsidenib can block the abnormal accumulation of 2-hydroxyglutarate (2-HG), thereby inhibiting the dedifferentiation and proliferation of tumor cells and achieving targeted therapeutic effects.

The main clinical indication of vorsidenib is relapsed or refractory low-grade glioma (LGG), especially patients with IDH1/2 mutation-positive patients. Studies have shown that IDH mutations are one of the key drivers of low-grade gliomas. By targeting this molecular abnormality, vorsidenib can delay tumor progression and improve patients' progression-free survival (PFS) and overall survival (OS).

Clinical trials have shown that vorsidenib has significant efficacy in patients with relapsed or refractory IDH1/2 mutated low-grade glioma. For example, in the II phase trial, voroxiranib was able to significantly prolong progression-free survival, with the median PFS exceeding 30 months, and the objective response rate (ORR) was also higher than traditional treatment options. The drug is generally well tolerated, and common adverse reactions include mild to moderate fatigue, nausea, mild abnormalities in liver function, etc., which can be managed through dose adjustment or symptomatic treatment .

In addition to low-grade glioma, vorsidenib is also exploring other treatments IDH Potential applications in mutation-related tumors, such as patients with the IDH1/2 mutated subtype of acute myeloid leukemia (AML). It has broad development prospects, but it has not yet been launched in China. If patients want to use it, they need to pay attention to international clinical trials and overseas supply channels. During treatment with vorsidenib, strict genetic testing is required to confirm the IDH mutation status, and an individualized treatment plan is carried out under the guidance of a professional neuro-oncologist to ensure efficacy and medication safety.

Reference materials:https://www.drugs.com/